急性単純性膀胱炎に対するCefixime(CFIX)の1日1回投与法の有用性について

Abstract

急性単純性膀胱炎76例にCefixime(CFIX)の効果を試した。BID群43例中UTI薬効基準に合致した33例では, 排尿痛消失28例(85%)であった。膿尿は正常化23例(70%)であった。細菌尿は陰性化24例(73%)で総合臨床有効率94%であった。主治医判定では有効率91%であった。UID群(一回200mgを一回投与)では28例中薬効基準合致22例中, 排尿痛消失は20例(91%), 膿尿正常化14例(64%), 細菌尿陰性化14例(64%)で総合有効率は96%であった。主治医判定では有効率82%であった。一般にE. coliに対して優れた感受性を示し, 副作用はUID群のうち1例のみ口内炎が発症したが変更により消失した

A comparative study of cefixime (CFIX), a new oral cephem antibiotic, was carried out at the Department of Urology, Nagoya University Hospital and its four affiliated hospitals to evaluate the clinical efficacy and safety of two dosage regimens of CFIX, given either in twice daily doses (BID group) or once daily dose (UID group), in the treatment of acute uncomplicated cystitis. Forty six female patients (BID group) were administered the daily dose of 200 mg in two divided doses for 3 days, 30 female patients (UID group) were administered 200 mg once daily for 3 days. The clinical efficacy was evaluated in 33 cases from the BID group and in 22 cases from the UID group, respectively, according to the criteria recommended by the Japan UTI Committee. In the BID group, the clinical efficacy was evaluated as excellent in 18 cases, moderate in 13 and poor in 2, with an overall clinical effectiveness rate of 94%. In the UID group, it was evaluated as excellent in 9 cases, moderate in 12 and poor in 1, with an overall clinical effectiveness rate of 96%. Safety was monitored in 71 patients, and only one case of stomatitis was seen in the UID group. This findings suggest that 200 mg once daily dosing regimen of cefixime is as effective as 100 mg twice daily dosing regimen in treatment of acute uncomplicated cystitis, and is well tolerated in terms of safety.